{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:42:22Z","timestamp":1784889742306,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005378","name":"Hacettepe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>We aimed to evaluate the prognostic factors and the role of stereotactic radiotherapy (SRT) as a re-irradiation technique in the management of progressive glioblastoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The records of 77 previously irradiated glioblastoma patients who progressed and received second course hypofractionated SRT (1\u20135 fractions) between 2009 and 2022 in our department were evaluated retrospectively. Statistical Package for the Social Sciences (SPSS) version 23.0 (IBM, Armonk, NY, USA) was utilized for all statistical analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median time to progression from the end of initial radiotherapy was 14\u00a0months (range, 6\u201368\u00a0months). The most common SRT schedule was 30\u00a0Gy (range, 18\u201350\u00a0Gy) in 5 fractions (range, 1\u20135 fractions). The median follow-up after SRT was 9\u00a0months (range, 3\u201380\u00a0months). One-year overall (OS) and progression-free survival (PFS) rates after SRT were 46% and 35%, respectively. Re-irradiation dose and the presence of pseudoprogression were both significant independent positive prognostic factors for both OS (<jats:italic>p<\/jats:italic>\u2009=\u20090.009 and <jats:italic>p<\/jats:italic>\u2009=\u20090.04, respectively) and PFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.008 and <jats:italic>p<\/jats:italic>\u2009=\u20090.04, respectively). For PFS, progression-free interval\u2009&gt;\u200914\u00a0months was also a prognostic factor (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). The treatment was well tolerated without significant acute toxicity. During follow-up, radiation necrosis was observed in 17 patients (22%), and 14 (82%) of them were asymptomatic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Hypofractionated SRT is an effective treatment approach for patients with progressive glioblastoma. Younger patients who progressed later than 14\u00a0months, received higher SRT doses, and experienced pseudoprogression following SRT had improved survival rates.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11060-024-04607-4","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T02:02:41Z","timestamp":1708567361000},"page":"295-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years\u2019 experience of a single center"],"prefix":"10.1007","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9813-9286","authenticated-orcid":false,"given":"Melek Tugce","family":"Yilmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Kahvecioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-6729","authenticated-orcid":false,"given":"Gozde","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0779-2691","authenticated-orcid":false,"given":"Sepideh","family":"Mohammadipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neyran","family":"Kertmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokcen Coban","family":"Cifci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faruk","family":"Zorlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"4607_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"4607_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rud\u00e0 R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170\u2013186. https:\/\/doi.org\/10.1038\/s41571-020-00447-z","journal-title":"Nat Rev Clin Oncol"},{"key":"4607_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.prro.2016.03.007","volume":"6","author":"AR Cabrera","year":"2016","unstructured":"Cabrera AR, Kirkpatrick JP, Fiveash JB, Shih HA, Koay EJ, Lutz S, Petit J, Chao ST, Brown PD, Vogelbaum M, Reardon DA, Chakravarti A, Wen PY, Chang E (2016) Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol 6:217\u2013225. https:\/\/doi.org\/10.1016\/j.prro.2016.03.007","journal-title":"Pract Radiat Oncol"},{"key":"4607_CR4","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/j.cell.2022.04.038","volume":"185","author":"FS Varn","year":"2022","unstructured":"Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, Cooper LAD, Malta TM, Wade TE, Sabedot TS, Brat D, Gould PV, W\u00f6ehrer A, Aldape K, Ismail A, Sivajothi SK, Barthel FP, Kim H, Kocakavuk E, Ahmed N, White K, Datta I, Moon HE, Pollock S, Goldfarb C, Lee GH, Garofano L, Anderson KJ, Nehar-Belaid D, Barnholtz-Sloan JS, Bakas S, Byrne AT, D\u2019Angelo F, Gan HK, Khasraw M, Migliozzi S, Ormond DR, Paek SH, Van Meir EG, Walenkamp AME, Watts C, Weiss T, Weller M, Palucka K, Stead LF, Poisson LM, Noushmehr H, Iavarone A, Verhaak RGW (2022) Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell 185:2184-2199.e2116. https:\/\/doi.org\/10.1016\/j.cell.2022.04.038","journal-title":"Cell"},{"key":"4607_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s11060-023-04407-2","volume":"164","author":"R De Pietro","year":"2023","unstructured":"De Pietro R, Zaccaro L, Marampon F, Tini P, De Felice F, Minniti G (2023) The evolving role of reirradiation in the management of recurrent brain tumors. J Neurooncol 164:271\u2013286. https:\/\/doi.org\/10.1007\/s11060-023-04407-2","journal-title":"J Neurooncol"},{"key":"4607_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13014-021-01767-9","volume":"16","author":"G Minniti","year":"2021","unstructured":"Minniti G, Niyazi M, Alongi F, Navarria P, Belka C (2021) Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol 16:36. https:\/\/doi.org\/10.1186\/s13014-021-01767-9","journal-title":"Radiat Oncol"},{"key":"4607_CR7","doi-asserted-by":"publisher","first-page":"657953","DOI":"10.1155\/2014\/657953","volume":"2014","author":"M Mart\u00ednez-Carrillo","year":"2014","unstructured":"Mart\u00ednez-Carrillo M, Tovar-Mart\u00edn I, Zurita-Herrera M, Del Moral-\u00c1vila R, Guerrero-Tejada R, Saura-Rojas E, Osorio-Ceballos JL, Arrebola-Moreno JP, Exp\u00f3sito-Hern\u00e1ndez J (2014) Salvage radiosurgery for selected patients with recurrent malignant gliomas. Biomed Res Int 2014:657953. https:\/\/doi.org\/10.1155\/2014\/657953","journal-title":"Biomed Res Int"},{"key":"4607_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s11060-015-1745-x","volume":"122","author":"G Minniti","year":"2015","unstructured":"Minniti G, Agolli L, Falco T, Scaringi C, Lanzetta G, Caporello P, Osti MF, Esposito V, Enrici RM (2015) Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas. J Neurooncol 122:559\u2013566. https:\/\/doi.org\/10.1007\/s11060-015-1745-x","journal-title":"J Neurooncol"},{"key":"4607_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1748-717X-8-161","volume":"8","author":"F Scholtyssek","year":"2013","unstructured":"Scholtyssek F, Zwiener I, Schlamann A, Seidel C, Meixensberger J, Bauer M, Hoffmann K-T, Combs SE, von Bueren AO, Kortmann R-D, M\u00fcller K (2013) Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort. Radiat Oncol 8:161. https:\/\/doi.org\/10.1186\/1748-717X-8-161","journal-title":"Radiat Oncol"},{"key":"4607_CR10","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00066-017-1161-6","volume":"193","author":"C Straube","year":"2017","unstructured":"Straube C, Elpula G, Gempt J, Gerhardt J, Bette S, Zimmer C, Schmidt-Graf F, Meyer B, Combs SE (2017) Re-irradiation after gross total resection of recurrent glioblastoma\u202f: spatial pattern of recurrence and a review of the literature as a basis for target volume definition. Strahlenther Onkol 193:897\u2013909. https:\/\/doi.org\/10.1007\/s00066-017-1161-6","journal-title":"Strahlenther Onkol"},{"key":"4607_CR11","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/cam4.1425","volume":"7","author":"SE Combs","year":"2018","unstructured":"Combs SE, Niyazi M, Adeberg S, Bougatf N, Kaul D, Fleischmann DF, Gruen A, Fokas E, R\u00f6del CM, Eckert F, Paulsen F, Oehlke O, Grosu A-L, Seidlitz A, Lattermann A, Krause M, Baumann M, Guberina M, Stuschke M, Budach V, Belka C, Debus J, Kessel KA (2018) Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score\u2014report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK). Cancer Med 7:1742\u20131749. https:\/\/doi.org\/10.1002\/cam4.1425","journal-title":"Cancer Med"},{"key":"4607_CR12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/nop\/npz017","volume":"6","author":"CH Chapman","year":"2019","unstructured":"Chapman CH, Hara JH, Molinaro AM, Clarke JL, Oberheim Bush NA, Taylor JW, Butowski NA, Chang SM, Fogh SE, Sneed PK, Nakamura JL, Raleigh DR, Braunstein SE (2019) Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. Neuro-Oncol Pract 6:364\u2013374. https:\/\/doi.org\/10.1093\/nop\/npz017","journal-title":"Neuro-Oncol Pract"},{"key":"4607_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11060-014-1524-0","volume":"120","author":"G Yazici","year":"2014","unstructured":"Yazici G, Cengiz M, Ozyigit G, Eren G, Yildiz F, Akyol F, Gurkaynak M, Zorlu F (2014) Hypofractionated stereotactic reirradiation for recurrent glioblastoma. J Neurooncol 120:117\u2013123. https:\/\/doi.org\/10.1007\/s11060-014-1524-0","journal-title":"J Neurooncol"},{"key":"4607_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97\u2013109. https:\/\/doi.org\/10.1007\/s00401-007-0243-4","journal-title":"Acta Neuropathol"},{"key":"4607_CR15","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"4607_CR16","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/jco.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963\u20131972. https:\/\/doi.org\/10.1200\/jco.2009.26.3541","journal-title":"J Clin Oncol"},{"key":"4607_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","volume":"14","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Wen PY, Cloughesy TF (2017) Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14:307\u2013320. https:\/\/doi.org\/10.1007\/s13311-016-0507-6","journal-title":"Neurotherapeutics"},{"key":"4607_CR18","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"4607_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-018-03064-0","volume":"142","author":"F Kazmi","year":"2019","unstructured":"Kazmi F, Soon YY, Leong YH, Koh WY, Vellayappan B (2019) Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis. J Neurooncol 142:79\u201390. https:\/\/doi.org\/10.1007\/s11060-018-03064-0","journal-title":"J Neurooncol"},{"key":"4607_CR20","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2009.25.6941","volume":"28","author":"SE Fogh","year":"2010","unstructured":"Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, Comber E, Maltenfort M, Dicker AP, Werner-Wasik M (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048\u20133053. https:\/\/doi.org\/10.1200\/JCO.2009.25.6941","journal-title":"J Clin Oncol"},{"key":"4607_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/s0360-3016(98)00416-7","volume":"43","author":"RS Hudes","year":"1999","unstructured":"Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, Downes B, Curran WJ Jr (1999) A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43:293\u2013298. https:\/\/doi.org\/10.1016\/s0360-3016(98)00416-7","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4607_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-2407-5-55","volume":"5","author":"D Vordermark","year":"2005","unstructured":"Vordermark D, K\u00f6lbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M (2005) Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 5:55. https:\/\/doi.org\/10.1186\/1471-2407-5-55","journal-title":"BMC Cancer"},{"key":"4607_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11060-014-1394-5","volume":"117","author":"M Flieger","year":"2014","unstructured":"Flieger M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, la Foug\u00e8re C, Ertl L, Linn J, Herrlinger U, Belka C, Niyazi M (2014) Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol 117:337\u2013345. https:\/\/doi.org\/10.1007\/s11060-014-1394-5","journal-title":"J Neurooncol"},{"key":"4607_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.adro.2018.06.005","volume":"3","author":"CJ Shen","year":"2018","unstructured":"Shen CJ, Kummerlowe MN, Redmond KJ, Martinez-Gutierrez JC, Usama SM, Holdhoff M, Grossman SA, Laterra JJ, Strowd RE, Kleinberg LR (2018) Re-irradiation for malignant glioma: toward patient selection and defining treatment parameters for salvage. Adv Radiat Oncol 3:582\u2013590. https:\/\/doi.org\/10.1016\/j.adro.2018.06.005","journal-title":"Adv Radiat Oncol"},{"key":"4607_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11060-013-1336-7","volume":"118","author":"TC Ryken","year":"2014","unstructured":"Ryken TC, Kalkanis SN, Buatti JM, Olson JJ (2014) The role of cytoreductive surgery in the management of progressive glioblastoma. J Neurooncol 118:479\u2013488. https:\/\/doi.org\/10.1007\/s11060-013-1336-7","journal-title":"J Neurooncol"},{"key":"4607_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.radonc.2021.12.019","volume":"167","author":"P Navarria","year":"2022","unstructured":"Navarria P, Pessina F, Clerici E, Bellu L, Franzese C, Franzini A, Simonelli M, Bello L, Santoro A, Politi LS, D\u2019Agostino GR, Casarotti A, Fernandes B, Torri V, Scorsetti M (2022) Re-irradiation for recurrent high grade glioma (HGG) patients: results of a single arm prospective phase 2 study. Radiother Oncol 167:89\u201396. https:\/\/doi.org\/10.1016\/j.radonc.2021.12.019","journal-title":"Radiother Oncol"},{"key":"4607_CR27","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s12094-018-1957-6","volume":"21","author":"E Br\u00e4utigam","year":"2019","unstructured":"Br\u00e4utigam E, Lampl C, Track C, Nieder C, Pichler J, Hammer J, Geinitz H (2019) Re-irradiation of recurrent glioblastoma as part of a sequential multimodality treatment concept. Clin Transl Oncol 21:582\u2013587. https:\/\/doi.org\/10.1007\/s12094-018-1957-6","journal-title":"Clin Transl Oncol"},{"key":"4607_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3349\/ymj.2018.59.2.194","volume":"59","author":"J Lee","year":"2018","unstructured":"Lee J, Ahn SS, Chang JH, Suh CO (2018) Hypofractionated re-irradiation after maximal surgical resection for recurrent glioblastoma: therapeutic adequacy and its prognosticators of survival. Yonsei Med J 59:194\u2013201. https:\/\/doi.org\/10.3349\/ymj.2018.59.2.194","journal-title":"Yonsei Med J"},{"key":"4607_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijrobp.2008.10.043","volume":"75","author":"PH Gutin","year":"2009","unstructured":"Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156\u2013163. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.10.043","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4607_CR30","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.ijrobp.2010.12.074","volume":"82","author":"KC Cuneo","year":"2012","unstructured":"Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP (2012) Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 82:2018\u20132024. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.12.074","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4607_CR31","doi-asserted-by":"publisher","first-page":"e18480","DOI":"10.7759\/cureus.18480","volume":"13","author":"EE Lovo","year":"2021","unstructured":"Lovo EE, Moreira A, Barahona KC, Ramirez J, Campos F, Tobar C, Caceros V, Sallabanda M, Sallabanda K (2021) Stereotactic radiosurgery for recurrent glioblastoma multiforme: a retrospective multi-institutional experience. Cureus 13:e18480. https:\/\/doi.org\/10.7759\/cureus.18480","journal-title":"Cureus"},{"key":"4607_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ijrobp.2017.08.038","volume":"100","author":"W Shi","year":"2018","unstructured":"Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, Souhami L, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Lessard N, Dignam JJ, Werner-Wasik M (2018) Investigating the effect of reirradiation or systemic therapy in patients with glioblastoma after tumor progression: a secondary analysis of NRG oncology\/radiation therapy oncology group trial 0525. Int J Radiat Oncol Biol Phys 100:38\u201344. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.08.038","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4607_CR33","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.22.00164","volume":"41","author":"CI Tsien","year":"2023","unstructured":"Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, Huang J, Algan O, Deb N, Portelance L, Villano JL, Hamm JT, Oh KS, Ali AN, Kim MM, Lindhorst SM, Mehta MP (2023) NRG Oncology\/RTOG1205: a randomized phase II Trial of concurrent bevacizumab and reirradiation versus Bevacizumab alone as treatment for recurrent glioblastoma. J Clin Oncol 41:1285\u20131295. https:\/\/doi.org\/10.1200\/JCO.22.00164","journal-title":"J Clin Oncol"},{"key":"4607_CR34","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1200\/jco.22.01785","volume":"41","author":"JPS Knisely","year":"2023","unstructured":"Knisely JPS, Fine HA (2023) Reirradiation for recurrent glioblastoma: what we know and what we do not. J Clin Oncol 41:1183\u20131188. https:\/\/doi.org\/10.1200\/jco.22.01785","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04607-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04607-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04607-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T13:14:03Z","timestamp":1713359643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04607-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["4607"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04607-4","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was conducted in compliance with the principles of the Helsinki Declaration and ethical\u00a0approval\u00a0was obtained from the institutional review board (SBA 23\/188, 2023\/04\u201310).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}